Patents by Inventor Kangze Dai

Kangze Dai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates
    Patent number: 11827614
    Abstract: The disclosure provides crystalline forms for certain synthetic intermediates for making belzutifan, a HIF-2? inhibitor, useful for the treatment of cancer. The disclosure also provides processes for isolating the crystalline forms.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: November 28, 2023
    Assignees: Merck Sharp & Dohme LLC, Werthenstein Biopharma GMBH
    Inventors: Stephen M. Dalby, Clinton Scott Shultz, Chintal Desai, Joshua Lee, Zhiwei Chen, Jungchul Kim, Nastaran Salehi Marzijarani, Tao Wang, Eric M. Phillips, Patrick Larpent, Het P. Patel, Haiheng Guo, Xin Wang, Kangze Dai, Lu Chen, Teng Li, Taotao Lu, Jianjun Duan
  • NOVEL SYNTHETIC PATHWAY TO BELZUTIFAN AND CRYSTALLINE PHASES OF SYNTHETIC INTERMEDIATES
    Publication number: 20220388974
    Abstract: The disclosure provides crystalline forms for certain synthetic intermediates for making belzutifan, a HIF-2? inhibitor, useful for the treatment of cancer. The disclosure also provides processes for isolating the crystalline forms.
    Type: Application
    Filed: May 20, 2022
    Publication date: December 8, 2022
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Stephen M. Dalby, Clinton Scott Shultz, Chintal Desai, Joshua Lee, Zhiwei Chen, Jungchul Kim, Nastaran Salehi Marzijarani, Tao Wang, Eric M. Phillips, Patrick Larpent, Het P. Patel, Haiheng Guo, Xin Wang, Kangze Dai, Lu Chen, Teng Li, Taotao Lu, Jianjun Duan